Yuying Xing

Dr. Yuying Xing

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YXYuying Xing
Yuying Xing
ABAmit Bahl
Amit Bahl
Background: COVID-19, influenza, and respiratory syncytial virus (RSV) are major respiratory infections with overlapping clinical presentations. Comparative data on the severity of these infections in hospitalized adults are limited, particularly across phases of the COVID-19 pandemic. Objectives: The objectives of this study are to compare the risk of severe outcomes among hospitalized patients with COVID-19, influenza, or RSV and to evaluate the role of vaccination and demographic subgroups using recent, real-world data. Design: This is a retrospective cohort study. Setting: Eight hospitals within the Corewell Health system in Michigan, USA, were studied. Participants: The participants included adults aged ≥ 18 years hospitalized between 1 January 2021 and 20 July 2024 with a principal diagnosis of COVID-19, influenza, or RSV. Main Outcomes and Measures: The primary outcome was a composite of ICU admission, mechanical ventilation, or in-hospital death. Multivariable Cox proportional hazard models were used to estimate adjusted hazard ratios (aHRs), with subgroup analyses in terms of vaccination status, age group, and time period. Results: Among 27,885 hospitalized patients (90.5% COVID-19, 7.2% influenza, 2.3% RSV), COVID-19 was associated with a higher risk of severe outcomes compared to influenza (aHR 1.30, 95% CI: 1.11–1.54). RSV showed no significant difference from influenza. Across all infection groups, older age (≥65 years), high comorbidity burden, and immunocompromised status were associated with an increased risk of severe outcomes. Recent COVID-19 vaccination was protective, particularly among older adults. Differences in severity were more pronounced in the pre-March 2022 period. Conclusions: Using one of the most recent large-scale datasets, this study is among the first to directly compare the severity of COVID-19, influenza, and RSV in hospitalized adults. COVID-19 continues to pose a higher risk of severe illness compared to the other viral infections. The findings underscore the importance of up-to-date vaccination and focused clinical strategies for older and high-risk individuals. This study offers timely evidence to guide future respiratory virus response strategies across hospital settings.

1 October 2024 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ABAmit Bahl
Amit Bahl
YXYuying Xing
Yuying Xing
SGS. Matthew Gibson
S. Matthew Gibson
EDEmily DiLoreto
Emily DiLoreto
Objective: Education and training in vascular access is a critical component to delivering quality vascular access care. Given that organizations must invest resources to implement and sustain high-quality vascular access programming, we aimed to demonstrate the cost effectiveness of a program (Operation STICK (OSTICK)) in the emergency department (ED). Methods: This was an observational cohort study conducted at a tertiary care academic center with 120,000 ED visits. Consecutive hospitalized adults with ultrasound-guided (DIVA) and traditionally-placed (non-DIVA) peripheral intravenous catheters (PIVC) in the ED were included in the analysis. Two groups (OSTICK and non-OSTICK) were compared in the analysis: OSTICK PIVCs were inserted by clinicians with formal, standardized training in peripheral venous access while non-OSTICK PIVCs were inserted by staff with basic departmental training in PIVC care. Cost factors included number of procedures, wait time to establish a PIVC, complications, and training. Effect was complication-free PIVC functionality. Multiple linear regressions were used to estimate incremental cost (ΔC), incremental effect (ΔE), and incremental net benefit (INB) of the OSTICK program. Results: From 10/1/2022 thru 3/31/2023, 21,259 PIVCs including 1681 OSTICK and 19,578 non-OSTICK PIVCs were included in the analysis. Average age was 64.8 and 53.7% were female. The estimate of incremental cost (ΔC) for each patient was -$83.175 (95% CI: -$103.953 to -$62.398; p<0.001), indicating that the OSTICK group saves money compared to the non-OSTICK group. The OSTICK group is also more effective at increasing the proportion of catheter dwell time relative to hospital length of stay (ΔE), with an estimate of 0.037 (95% CI: 0.016 to 0.059; p<0.001), compared to those in the non-OSTICK group. The estimated incremental cost-effectiveness ratio (ICER) for the OSTICK group compared with the non-OSTICK group was −$221.964 (95% CI: -$177.400 to -$381.716) per ten percentage points of PIVC dwell time to hospital length of stay increase. Conclusions: Strategic investment in vascular access education and training can yield impressive financial returns while simultaneously enhancing vascular access outcomes. It is imperative for organizations to recognize the significant impact of such initiatives and prioritize the implementation of comprehensive programs.

1 March 2025 in Journal of Shoulder and Elbow Surgery
Verified
Journal Article
Open access
RCRishi Chatterji
Rishi Chatterji
BFBrandon T. Fisher
Brandon T. Fisher
AAAvianna Arapovic
Avianna Arapovic
YXYuying Xing
Yuying Xing
JWJ. Michael Wiater
J. Michael Wiater
Shoulder arthroplasty systems are transitioning toward modular prosthesis options with the goal of reducing complication profiles and increasing range of motion. Modularity may increase the potential for fretting, corrosion, and subsequent release of metal ions. The purpose of this study was to identify associations between implant designs, metallurgy, patient characteristics, and serum metal ion levels in patients undergoing revision shoulder arthroplasty. Fifty-one patients who underwent revision shoulder arthroplasty were retrospectively reviewed based on prospectively collected data. All patients had serum metal ion levels (titanium, cobalt, chromium) measured in parts per billion (ppb) before their revision arthroplasty. Trends and correlations to serum ion levels were examined based on implant materials, number of modular components, and patient characteristics. Twenty-one patients had anatomic total shoulder arthroplasty (aTSA), and 30 had reverse total shoulder arthroplasty (rTSA). The average age at primary arthroplasty was 64.7 years (49.0-84.0). The average term of implant was 4.83 years (0.18-21.0). Forty-six patients (90%) had titanium-based humeral stems. Twenty-one (100%) aTSA humeral heads were composed of cobalt chrome. Five patients with aTSA had hybrid titanium and polyethylene glenoid components. In those with rTSA, 30 (100%) had glenoid components composed of titanium baseplates and cobalt chrome glenospheres. Titanium ion levels were significantly higher in patients with greater than 7 total modular components (12.6 vs. 6.09 ppb, P = .008). Titanium ion levels were significantly higher in patients with greater than 4 modular components when excluding screws (12.1 vs. 5.06, P = .038). The number of modular components did not have a statistically significant effect on cobalt or chromium serum ion levels. Patients with intraoperative metallosis during revision surgery had titanium ion levels 10.51 units higher on average (P = .009) than those without metallosis. There was no difference in titanium (P = .63), cobalt (P = .29), or chromium (P = .58) levels in those patients with a proven infection compared to those without. Increasing modularity in primary TSA should be weighed with the potential for increased serum metal ion levels, particularly titanium. Although the systemic effects of elevated serum titanium remain largely unknown, it may be a predictor for occult corrosion or need for revision. Metallosis poses challenges in the revision setting; however, the implications of increased serum metal ion levels on clinical outcomes after revision shoulder arthroplasty requires further studies.

13 November 2025 in Infectious Disease Reports
Verified
Journal Article
Open access
PDF file
YXYuying Xing
Yuying Xing
ABAmit Bahl
Amit Bahl
Background: The duration of protection that COVID-19 vaccination provides against severe outcomes remains uncertain. Accurately defining this timeframe is critical for informing effective vaccination policies and booster strategies. This investigation aimed to quantify the length and durability of vaccine-conferred protection against severe disease, delivering evidence to guide public health decision-making. Methods: We conducted a multi-site cohort study to evaluate the relationship between time since last COVID-19 vaccination and the risk of severe infection among emergency department (ED) patients with a principal diagnosis of COVID-19. Vaccination status was categorized by time since the last documented dose: unvaccinated, 0–6 months, 7–12 months, 13–18 months, and 19–24 months. The primary outcome was severe COVID-19, defined as ICU admission, mechanical ventilation, or in-hospital death. Inverse Probability of Treatment Weighting (IPTW) was used to adjust for baseline confounding based on age group, sex, race, comorbidity burden, immunocompromised status, and calendar time period (pre-2023 vs. post-2023). Cox proportional hazards models were used to estimate adjusted hazard ratios (aHRs) for each vaccination interval compared to unvaccinated patients. Results: Between 1 December 2021, and 20 July 2024, 42,124 ED encounters were included in the analysis. In IPTW-weighted models, vaccination within 0–6 months (aHR 0.73, 95% CI 0.64–0.83), 7–12 months (aHR 0.72, 95% CI 0.64–0.82), and 13–18 months (aHR 0.67, 95% CI 0.57–0.79) was associated with a significantly reduced risk of severe outcomes. However, no significant protection was observed at 19–24 months (aHR 0.95, 95% CI 0.80–1.14). In age-stratified analyses, protection persisted longer in individuals aged ≥65 years than in those aged 50–64. Older age, male sex, comorbidities, and immunocompromised status were also associated with increased risk. Conclusions: COVID-19 vaccination provides sustained protection against severe outcomes for up to 18 months, after which effectiveness declines substantially. These findings support booster dose strategies based on time since last vaccination and targeted prioritization for high-risk populations.

26 December 2025 in PLOS ONE
Verified
Journal Article
Open access
COCharlotte O’sUllivan
Charlotte O’sUllivan
NMNicholas Mielke
Nicholas Mielke
YXYuying Xing
Yuying Xing
ABAmit Bahl
Amit Bahl
Objective: This retrospective, multicenter study aimed to investigate disparities in peripheral intravenous catheter (PIVC) placement wait times among patients in emergency departments (EDs), focusing on the impact of factors such as race, sex, age, and comorbidities. Methods: Electronical health record (EHR) data from four EDs within Corewell Health System were analyzed for adult patients who underwent PIVC placement between January 1st, 2021 and January 31st, 2023. Multivariable linear regression models were employed to analyze associations between patient demographics (including race, sex, age, and comorbidities) and PIVC placement wait times. Adjustments were made for Charlson comorbidity index, emergency severity index, hospital size, obesity, and method of PIVC insertion. Results: Among 319,938 PIVC placements analyzed, significant disparities were observed: Black patients waited 9.65% longer for PIVC placement compared to White patients (p < 0.001). Women experienced a 6.67% longer wait time than men (p < 0.001). Obese and elderly patients also experienced prolonged wait times. These disparities persisted across both ultrasound-guided and traditionally placed PIVCs. Conclusions: This study underscores substantial disparities in PIVC placement wait times in EDs, influenced by race, sex, age, and comorbidities. Addressing these disparities is crucial for improving equity in emergency care delivery. Future research should focus on implementing targeted interventions to mitigate these disparities and enhance timely access to essential medical interventions for all patient populations.